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Abstract 
Introduction: The coronavirus disease (abbreviated COVID-19) pandemic caused by SARS-CoV-2 has devastated 
the world in the space of just a few months. Since it was first reported in December 31, 2019 in the Hubei province 
of China, at the time of writing, over 2 million people have been infected, with over 127,598 deaths in 202 countries 
and territories. Records of global distribution show a steady increase, although the USA is leading in its distribution, 
with Italy reporting close to 20,000 deaths. The purpose of this rapid review is to synthesize available evidence on 
the epidemiology, pathogenesis, diagnosis and public health control measures to inform policy, programs and 
research on COVID-19. 
Methods: A rapid review method was employed using PubMed and Google Scholar search engines. Journal articles, 
reports and government documents were included in our search, which is focused on the disease epidemiology, 
advancements in diagnostics, treatment and vaccines, public health control measures, and psychosocial interventions 
for health care providers. The contents of the identified articles were examined and abstracted by a team of 
investigators. The concepts represented by the individual reviews were collated to give a complete picture of 
COVID-19 based on the evidence we have so far. The search period spanned December 30, 2019 to April 15, 2020.  
Findings: The severity of the disease and its fast spread, three times faster than the flu, has challenged the health 
systems of almost every country in the world. Although, for now, the case burden remains low in Africa, the impact 
of COVID-19 is anticipated to be severe if it becomes widespread. Efforts to curb the pandemic, involving 
prevention, disease surveillance, contact tracing, clinical management and the development of new treatments and 
diagnostics, is ongoing across the globe. While writing this review, more than 73 vaccines are at the exploratory or 
preclinical stage, while two are in phase I clinical trials. Yet, non-pharmaceutical interventions are critical to 
stopping the spread of the virus. Africa, in particular, should put extra effort into making preventive public health 
measures work, because health systems in the continent are too weak to withstand the effect of the pandemic should 
it hit hard, and the economic implications of extreme control measures following a delayed response would be 
severe. On the bright side, the lessons drawn from this pandemic are likely to improve the preparedness and response 
to similar future outbreaks and pandemics. [Ethiop. J. Health Dev. 2020; 34(2):129-140] 
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Introduction 
A lung disease of an unknown cause was identified 
among a cluster of patients in Wuhan province, China, 
on December 31, 2019 (1). On January 07, 2020 the 
Chinese authorities confirmed that they had isolated a 
new virus from the coronavirus family (2019 novel 
coronavirus, 2019-nCoV) (1). Later, the International 
Committee on Taxonomy of Viruses re-named this virus 
as severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) (2).  
 
SARS-CoV-2 is the third outbreak caused by the 
coronavirus family in the past two decades. Unlike the 
previous two, this pandemic has affected the entire 
world within a short time (3). Severe acute respiratory 
syndrome (SARS-CoV), which occurred in 2002, 
claimed the lives of 916 people after infecting nearly 
8,422 (4); Middle East respiratory syndrome 
coronavirus (MERS-CoV), reported in 2012, infected 
2,229 and left 791 people dead. The MERS outbreak 
was relatively localized, with 83% of cases reported by 
the Kingdom of Saudi Arabia, although sporadic 
occurrences were reported in Europe, the USA and 
northern Africa (5). Compared to SARS-CoV and 
MERS-CoV, the rapid transmission of SARS-CoV-2 
has been exceptional, with its spread covering more than 
202 countries and territories and affecting over 2 million 
people across the globe (3). The pandemic has continued 
to spread and overwhelm the health systems of most of 
the affected countries.  However, it is expected to be 
more damaging to African countries, as most have 
under-resourced health facilities and fragile health 
systems (6). Despite the immense public health and 
economic impact of the pandemic, we still do not have 
concrete evidence to guide the direction of research and 
policy.  
 
Day by day, ever-changing evidence about the disease 
indicates that the quest for more evidence has grown 
exponentially. In the past three months, nearly 600 
clinical trials have been proposed and over 150 
diagnostic tests have been developed (7). This and more 
evidence in the making has made the information on 
COVID-19 overwhelming. However, there is still a 
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growing interest in acquiring more evidence to guide 
policy and pandemic response interventions (8). The 
knowledge management unit of the Centre for 
Innovative Drug Development and Therapeutic Trials 
for Africa (CDT-Africa) (9) aims to synthesize the 
available evidence on the epidemiology, pathogenesis, 
diagnostics and public health control measures to inform 
policy, programs and research.  
 
Methods 
Design: We employed a rapid review of articles 
published from December 30, 2019 to April 15, 2020 on 
SARS-COV-2 and COVID-19 (10). Although numerous 
researches are underway and considerable number of 
publications are already available, there is not yet 
conclusive evidence in relation to all aspects of the 
disease. This rapid review would help to scope 
fragmented, opinion-based, large-scale and sometimes 
contradictory resources for easy use. 
 
Search strategy: We searched the PubMed and Google 
Scholar databases employing the key terms “COVID-
19”, “SARS-CoV-2”, “coronavirus” and “viral 
infections”. This was supplemented by accessing 
additional resources from the databases and websites of 
academic and research institutions, and guidelines of 
international organizations such as the World Health 
Organization (WHO) and Centers for Disease Control 
and Prevention (CDC), as we saw fit.  
 
Inclusion criteria: Considering the broad scope of the 
review, we were flexible with our inclusion criteria. 
Publications ranging from observational to experimental 
studies, and from grey literature to editorials and 
perspectives, were included. 
 
Outcomes: The outcomes were those concerning the 
pathogenesis, descriptive epidemiology, treatments, 
vaccines, diagnostics, personal protective equipment 
and public health control measures in relation to 
COVID-19, and recommendations pertaining to the 
wellbeing of health care professionals.  
 
Data extraction and analysis: We identified 78 
publications on a range of topics concerning COVID-19. 
The articles were grouped under the following headings: 
the nature of the virus, epidemiology and pathogenesis 
of the disease, laboratory diagnosis and developments in 
diagnostics, drugs in use and under trial, public health 
control measures, and psychosocial interventions for 
health care professionals.  
 
The research team was comprised of six academics with 
different backgrounds in the field of health sciences. 
Each member rigorously reviewed eight to 10 articles 
and summarized the content separately. Summaries of 
the separate reviews were presented and discussed daily 
at virtual meetings. The discussions were aimed at 
sharing understanding and to reach consensus on the gist 
of the publications reviewed by the individual members 
of the team.  
 
Six consecutive video conferences were held back to 
back to discuss the findings from the individual reviews. 
At every meeting, the investigators took turns to present 
their summary of the findings from their review. The 
presentations were followed by inputs and further 
discussions from the rest of the team. These 
deliberations helped to evaluate the content, reach 
consensus and, if relevant, expand on the interpretation 
to be drawn from each article. At the end, the individual 
reviews were collated, and the seventh video conference 




The virus: Coronavirus disease 2019 (COVID-19) is an 
illness caused by a novel coronavirus now called severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2). This strain of the coronavirus family was first 
identified among a cluster of respiratory illness cases in 
Wuhan City, Hubei province, China (1). Corona is a 
name given to a large family of respiratory disease-
causing viruses under the family Coronaviridae, which 
was first isolated in the1960s. In the past, different 
strains that belong to this family have crossed over from 
animals, e.g. bats, birds and warm-blooded flying 
vertebrates, and infected humans (11).  
 
Based on antigenic relationships of the spike (S), 
membrane (M), nucleocapsid (N) proteins and viral 
genetic phylogeny, coronaviruses are classified into four 
groups: alpha, beta, gamma and delta (4,12). Though 
coronaviruses mainly infect animals, there are seven 
strains known to infect humans, called the Human 
Coronaviruses (HCoVs). The most common of these are 
HCoV-229E (alpha), HCoV-OC43 (alpha), HCoV-
NL63 (beta) and HCoV-HKU1 (beta) (13). These 
subgroups are associated with a range of respiratory 
diseases including the common cold, bronchiolitis and 
pneumonia. The other HCoVs are severe acute 
respiratory syndrome (SARS)-CoV (beta), Middle East 
respiratory syndrome (MERS)-CoV (beta) and the 
newly discovered 2019 novel coronavirus (2019-nCoV). 
SARS and MERS are known for causing outbreaks in 
2002 and 2014 respectively, and they are referred to as 
agents of great public health threat (14,15). Both are 
severe and had a high case fatality rate (Table 1), but 
SARS-COV-2 has covered a significantly wider 
geographic area.  
 
Pathogenesis: Coronaviruses are enveloped positive-
sense RNA viruses, with their size ranging from 60 to 
140 nm in diameter. They have spike-like projections on 
their surface, giving them a crown-like appearance 
under the electron microscope, which explains the name 
“corona”. Studies reveal that the virus enters the 
respiratory mucosa using the angiotensin-2 (ACE-2) 
receptor on the surface of the mucosal cells. This 
justifies why the virus commonly targets the respiratory 
system (14,16,17).  
 
Disease symptoms: The incubation period of COVID-
19 ranges from two to 14 days (1,18). The clinical 
manifestations of the mild to moderate disease mimics a 
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regular flu, presenting headache, fever, dry cough and 
fatigue. In some cases, a productive cough, sore throat, 
haemoptysis, diarrhoea and lymphopenia may be part of 
the picture. At later stages (5.2 to 8 days from the time 
of infection), dyspnoea and acute respiratory distress 
syndrome (ARDS) can be observed, and multiorgan 
dysfunction is also reported in some patients 
(2,16,17,19).  
 
Around 80% of people who are infected either do not 
exhibit the manifestations or will only have minimal 
symptoms. Mild to moderate symptoms are observed in 
15% of infected people, and 4% to 5% warrant intensive 
care in hospitals. The median time interval between the 
onset of the first symptom to hospitalization is 7 days 
and the median hospital stay, from admission to 
discharge, is 10 days (19). The median number of days 
from infection to death is 14 (ranging from 6 to 41 days) 
(18). Factors such as age and co-morbidity dictate the 
difference in the duration between the onset of 
symptoms and death. People older than 70 years and 
those with comorbidities have a short duration and are 
prone to develop severe complications (2).  
 
Epidemiology – Global: The first five cases were 
reported from China in mid-December 2019; they were 
hospitalized for ARDS and one of them died after 
admission. On December 31, 2019, a cluster of cases of 
pneumonia of unknown cause were detected in Wuhan 
City, the capital of Hubei province. By January 02, 
2020, 41 hospital-admitted patients were diagnosed for 
COVID-19 infection and 10 days later the WHO 
declared the advent of an outbreak caused by a novel 
coronavirus, 2019 (2019-nCoV) (1). By January 22, 
2020, a total of 571 cases and 17 COVID-19 related 
deaths had been reported from 25 provinces (districts 
and cities) of China (20). Following this, a report on 
January 30 indicated the emergence of 90 new cases in 
16 nations from five out of the seven continents (only 
sparing Africa and Antarctica). At this point, the number 
of confirmed cases in China had reached 7,734. As a 
result, the WHO declared the COVID-19 outbreak as a 
global public health emergency and officially renamed 
it as severe acute respiratory syndrome coronavirus-2 
(SARS- CoV-2) (13,21). On March 11, 2020 it was 
declared a global pandemic (22). 
 
When we prepared this report (April 15, 2020), the 
pandemic had affected more than 202 countries and 
boundaries, infecting 2 million people and causing 
127,000 deaths (23,24). The United States of America 
reported the highest number of cases (614,246), 
followed by Spain (174,060), Italy (164,488) and France 
(143,303). The other most affected countries were 
Germany, United Kingdom, China and Iran. Of the 
confirmed COVID-19 patients, 95% had mild to 
moderate illness and 5% were seriously sick needing 
critical care (25). Taking the total number of infected 
people as a denominator (485,362), 24.2% have 
recovered from the disease so far (23,24). However, this 
proportion would be significantly higher (i.e. 79%) if we 
take cases with the reported outcome as a denominator.  
 
Epidemiology – Africa: In Africa, the first COVID-19 
case was reported from Egypt on February 14, 2020. 
Since then, 52 African countries have been affected, 
reporting 16,302 cases, 880 deaths, and 340 recoveries 
in the continent. South Africa has the largest number of 
cases in the continent (2,415), followed by Egypt, with 
a total of 2,350 cases. Morocco (1,888), Algeria (2,070), 
Tunisia (747) and Burkina Faso (528) are the other 
African countries with a high number of cases. Even 
though South Africa has a high number of cases, only 27 
deaths have been reported, while 164 deaths have been 
reported in Egypt, 326 in Algeria and 126 in Morocco 
(18,26,27). 
 
Epidemiology – Ethiopia: In Ethiopia, the first 
coronavirus case was reported in Addis Ababa on March 
12, 2020. The index case was a 48-year-old Japanese 
man who came to Ethiopia from Burkina Faso on March 
04, 2020. According to the Ethiopian Public Health 
Institute, by April 15, 2020, a total of 85 confirmed 
cases, three deaths and two recoveries have been 
reported. The two initial cases were transferred back to 
their home countries and there were 19 active cases 
under medical treatment in a designated treatment centre 
(27,28). 
 
Disease transmission: COVID-19 is transmitted 
through droplets produced when coughing or sneezing. 
After leaving the infected person, the droplets can travel 
up to 2 meters and stay suspended in the air or get 
deposited on surfaces or the ground for varying periods. 
The virus can remain viable on surfaces for days if the 
atmospheric conditions are favourable. But common 
disinfectants such as ethyl alcohol (70%), sodium 
hypochlorite and hydrogen peroxide can effectively 
disinfect materials in less than a minute following 
application (29). 
 
Both symptomatic and asymptomatic people can be 
sources of infection. Even though conclusive findings 
are not yet available, experts believe that people can stay 
infectious for as long as the symptoms last and even on 
clinical recovery. The portal of entry for the virus is 
either the respiratory system, when the droplets are 
inhaled, or touching the eyes, buccal or nasal cavity with 
a contaminated hand (17,23,30). The portal of exit is the 
same, and a person does not need to be symptomatic to 
transmit the infection, as long as they contaminate their 
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Table 1: Comparison of COVID-19 with the previous HCoV global outbreaks 
 SARS MERS COVID-19 
Year, origin November 2002, 
Guangdong province of 
China  
2012, Saudi Arabia and many 
countries in the Arabian 
Peninsula 




2-14 days 5-6 days after exposure, but can 
range from 2-14 days 
2-14 days 
 
Symptoms Fever, chills, and body 
aches, progressing to 
pneumonia 
Fever, chills, headache, cough, 
shortness of breath, diarrhea 
and nausea/vomiting 
Fever, cough, shortness of breath, 
headache, fatigue and sore throat 
Reservoir Bats and intermediate 
host civets 
Bats and intermediate host 
camels 
Bats; the intermediate animal has 
not yet been identified  
Total cases 8,422 2,229 2,014,554 
Deaths 916 791 127,598 
CFR 10.8% 34.3% 3-5% 
Transmission 
rate (Ro) 
Ro - 2 Ro - (2.5 - 8.09) Ro - (3.6 - 4) 
Note: Reprinted from “COVID-19:Lessons from SARS and MERS” by Park.M, Thwaites R.S, Openshaw P.J, 
2020, European Journal of Immunology,50,308-316; Worldometer 2020. COVID-19 coronavirus pandemic. 
Mortality rates: The overall case fatality rate (CFR) 
among those initially infected was calculated as 1.6%, 
but recent estimates (around the beginning of March) 
from the WHO indicated an increase in the CFR to 3.4% 
(23). Mortality from COVID-19 differs based on 
background characteristics, such as age, with different 
countries reported varying CFRs. Age-specific CFR 
indicates a significantly higher mortality among the 
elderly than the general population. So far, Italy has 
reported the highest CFR (10.8%), which is substantially 
higher than China (2.3%). The difference in 
demographics and culture of the people in the two 
countries is argued to explain the difference in CFR. 
Italy has a large proportion of elderly population and 
young people have close social ties with their parents 
and grandparents. These frequent social encounters 
between family members might have exposed the 
vulnerable elderly population to the disease. The second 
argument is that patients in Italy were taking ibuprofen 
as a symptomatic therapy, but latterly clinicians advised 
against its use, assuming the drug to exacerbate the 
proliferation of the virus (31,32). In contrast, Germany 
has had the lowest death rate from COVID-19 (0.6%), 
with the second lowest rate reported in USA and 
Switzerland (1.4%) (23). 
Risk factors – Age: According to a WHO report and 
related studies, older age is strongly associated with 
higher mortality from COVID-19. The mortality rate 
among patients older than 80 years is reported to be 
15%, but under 1% for those younger than 40 years. So 
far, no death has been reported among children in the 
age range of 0 to 9 years (19,23,33). 
Risk factors – Sex: COVID-19 is reported to have a 
significant male preponderance, in terms of both 
morbidity and mortality. Thus far, 63.1% of patients 
 
have been males and the mortality among this group is 
4.7%, which is more than twice the rate among females 
(1.7%). Higher smoking rates and lower personal 
hygiene practices among men compared to women are 
believed to explain the skewed distribution (13,19). 
Risk factors – Cigarette smoking: The association 
between cigarette smoking and COVID-19 remains 
controversial. A recent update from the WHO suggests 
that using tobacco products increases the risk of 
infection (34). Bringing the hand close to the mouth 
while smoking may allow entry of the virus into the 
body and sharing cigarettes can facilitate the 
transmission. In general, cigarette smoking predisposes 
the respiratory system to infection, although two 
systematic reviews found no association between 
smoking and either developing COVID-19 or mortality 
from the disease (35-37). 
Risk factors – Comorbidities: According to the 
Worldometer data, the death rate among patients with 
pre-existing cardiovascular disease, diabetes, 
hypertension and chronic respiratory diseases is 10.5 %, 
7.3%, 6.3% and 6.0%, respectively (23). However, 
among patients with no underlying conditions, the 
number drops to 0.9%. Related epidemiological studies 
also support this finding (16,19,32). In establishing the 
association between sociodemographic characteristics 
and the risk of infection, it is worth noting the effect of 
such underlying health conditions in the causal pathway.  
Diagnostics: The reverse real-time polymerase chain 
reaction assay (rRT-PCR) remains the primary 
diagnostic approach for SARS-CoV-2 (38-40). The test 
can run on a variety of clinical specimens, including 
bronchoalveolar lavage fluid, fibro bronchoscopy brush 
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biopsies, sputum, nasal swabs, pharyngeal swabs, feces, 
or blood (40). 
This current diagnostic approach is high maintenance, 
requiring well-equipped laboratories and highly trained 
staff. In addition, the multiple procedures involved 
between specimen collection and producing the result 
makes it difficult to use and time-consuming (40,41). A 
short turnaround time from giving a sample to obtaining 
the result increases the effectiveness of the control 
measures, since the subsequent public health 
interventions hinge on the test result and how fast it is 
obtained. Furthermore, going to and staying around 
testing facilities can increase the risk of transmission, 
not to mention the strain on the limited health care 
resources (40). 
The rapid spread and non-specific presentation of the 
infection warrants an accurate, cheap and easy-to-use 
diagnostic tool for point of care (POC) testing (38,40-
42). Because of this, the WHO made it a priority to assist 
and lead research projects in the area of low tech and 
rapid POC diagnostics for use at the community level 
(43). As part of this initiative, diagnostic companies 
such as FIND are working closely with the WHO and 
providing technical support to partners, building their 
capacity through staff training to ensure access to 
accurate and high-quality diagnostic test kits, 
particularly for low- and middle-income countries (44).  
Aiming to expedite the approval process for new tests, 
the U.S. Food and Drug Administration (FDA) 
announced a new guideline which shortens the previous 
lengthy procedures (45). As of March 28, 2020, the FDA 
has approved two coronavirus tests that can be used at 
POC (46,47). The first test was granted emergency use 
authorization (EUA) on March 20, 2020. This test is 
intended for use in patient care settings and can produce 
the result in less than 45 minutes. A nasal swab or a 
saline wash using a small catheter can be used to collect 
a specimen for the test. Patients reported that neither 
approaches are comfortable, but the wash avoids the use 
of a swab, which is already in short supply (46). The 
second test was granted approval on March 27, 2020 for 
the fastest molecular POC developed so far to test 
COVID-19. The test delivers positive results in no more 
than five minutes and negative results in 13 minutes. 
The test is fit for use in a wide range of health care 
settings such as physicians’ offices, emergency care 
clinics and hospital emergency departments (47). 
In the early days of the outbreak in Wuhan, the standard 
laboratory nucleic acid sequencing analysis was used to 
test for the infection. But it was labour-intensive and 
costly, and there was a severe shortage of test kits. 
Hence, the National Medical Products Administration of 
China took immediate action to speed up the work of 
biotech companies to develop detection kits. As a result, 
the first kit was introduced on January 13, 2020, with 
enough supply made available after two weeks. From 
China’s experience, it is apparent that having specific, 
reliable, accurate and fast detection methods to screen 
infected and non-infected people plays a major role in 
limiting the spread of the virus (48). In Africa, there 
were only two countries with some diagnostic capacity 
at the start of the pandemic. Initially, Ethiopia did not 
have test facilities, and samples were sent to South 
Africa for analysis, which required complex 
coordination activities and continuous communication. 
Ethiopia started in-country testing for the virus on 
February 7, 2020, and the results are reportedly 
produced on the same day (49). 
Advancements in drug and vaccine development: To 
date, there are no approved drugs and vaccines in the 
market to prevent or treat COVID-19 (39). The WHO’s 
working recommendation (Table 2) for suspected and 
actual cases of COVID-19 is health facility-based triage 
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Table 2: Levels of severity and corresponding treatment recommendations for COVID-19 (adopted 
from WHO, 2020)40 
Level of severity Manifestation of 
COVID-19 
Recommendation 
Mild Mild clinical symptoms. 
No pneumonia 
manifestation in imaging. 
No hospital interventions required. 
Isolation of patients to contain virus transmission.  
 
Patients can be given symptomatic treatment,  
such as antipyretics. 
 
Counsel patients about signs and symptoms of 
complicated disease so that they will seek urgent care. 
Moderate Symptoms such as fever 
and respiratory tract 
symptoms, and 
manifestations of 
pneumonia can be seen in 
imaging. 
Symptomatic treatment, and treatment of  
pneumonia with antibiotics. 
Severe Respiratory rate ≥ 30 
breaths/min; oxygen 
saturation ≤ 93% at a rest 
state; arterial partial 
pressure of oxygen 
(PaO2)/oxygen 
concentration (FiO2) ≤ 
300 mmHg. 
 
Patients with > 50% 
lesions progression within 
24 to 48 hours in lung 
imaging. 
Oxygen therapy: recommended for patients with 
respiratory distress and severe acute respiratory 
infection.  
 
Oxygen supplementation treatment can correct 
hypoxemia, relieving secondary organ damage caused 
by respiratory distress and hypoxemia. 
 
Closely monitor patients for signs of clinical 
deterioration, such as rapidly progressive respiratory 
failure and sepsis, and respond immediately with 
supportive care interventions. 
Critical Occurrence of respiratory 
failure requiring 
mechanical ventilation; 
presence of shock; other 
organ failure that requires 
monitoring and treatment 
in the intensive care unit. 
 
Artificial liver support system and blood purification 
can effectively diminish inflammatory mediators and 
cytokine cascade, and prevent the incidence of shock, 
hypoxemia and respiratory distress syndrome. They can 
also improve multiple organ functions, including of the 
liver and kidney. Thus, they can increase treatment 
success and reduce mortality from severe disease. 
 
Mechanical ventilation (could be non-invasive or 
invasive). 
 
Despite the lack of approved drugs and vaccines for 
COVID-19, the scientific community has been looking 
into repurposing drugs approved for other diseases to 
treat COVID-19. As of  March 29, 2020, there were 209 
clinical trials registered at clinicaltrials.gov (50). 
However, the actual number of clinical trials is 
estimated to be over 500. The trials include drugs, 
dietary supplements, vaccines, surgical procedures, and 
a wide range of products (43). The drugs under 
investigation include anti-viral hydroxychloroquine and 
chloroquine, protective monoclonal antibodies, and 
human convalescent serum. 
 
Lopinavir–ritonavir 
Lopinavir is an HIV-1 protease inhibitor, often 
combined with ritonavir to increase its half-life. The 
drug has shown promise to inhibit coronavirus 
replication in vitro, and in previous studies it has 
improved the clinical outcome of patients with MERS-
CoV when used in combination with interferon. 
Currently, a clinical trial is under way to study the safety 
and efficacy of the drug for SARS-CoV-2 (44,45). 
According to an experience from designated hospital for 
COVID-19 patients, in China, the administration of 
lopinavir–ritonavir (two capsules, orally, every 12 
hours) with Arbidol (umifenovir) (200mg, orally, every 
12 hours) for 49 patients resulted in a negative nucleic 
acid test result, however it was reported that these results 
lasted for an average duration of 13.5 days (42). 
Remdesivir 
Remdesivir is an RNA polymerase inhibitor. Both in 
vitro and in vivo experiments have shown promising 
results against coronavirus. Currently, a randomized 
controlled trial is under way to test the efficacy of the 
drug in patients with mild to moderate and severe 
COVID-19. This drug has been used in the USA, China 
and Italy on a compassionate basis to treat small 
numbers of patients with severe COVID-19 
(39,44,46,47).  
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Hydroxychloroquine/Chloroquine 
Chloroquine is an anti-malarial drug sometimes used to 
treat certain inflammatory conditions, such as 
rheumatoid arthritis and systemic lupus erythematosus. 
Hydroxy chloroquine is a prodrug for chloroquine. 
These drugs are currently under investigation for 
prophylaxis, as well as treatment, of patients with mild, 
moderate or severe COVID-19 (51). In China, 
chloroquine phosphate was given to adults aged 18-65 
years of age (weight ≥ 50 kg: 500 mg twice a day for 
seven days; weight ≤50 kg: 500 mg twice a day for the 
first two days, 500 mg once a day for the following five 
days) (52). It is important to note that the drug has a 
narrow safety margin between the therapeutic and toxic 
dose. Therefore, self-treatment using these drugs is not 
advised, as inappropriate use may cause fatal 
complications (53). 
 
Convalescent plasma treatment 
This involves the administration of antibodies extracted 
from the blood plasma of a recovered COVID-19 patient 
into an individual in the hope of treating the patient or 
preventing future transmission. If deemed successful, 
this approach promises a great potential due to the 
availability of recovered COVID-19 patients in great 
numbers who can provide immunoglobulin-containing 
serum. However, it requires caution and use of the right 
technology not to risk inadvertently transmitting other 
pathogens or trigger immunologic reaction in the 
recipient (54). 
 
Vaccines: Most of the vaccines under trial are S-protein 
based and are intended to induce an immunoreaction. 
The S-protein act in the SARS-CoV by producing 
neutralizing antibodies and T-cell responses (55). 
Among those under investigation is mRNA1273 
vaccine, which has been expedited from the design stage 
straight to phase I clinical trial for its effect on SARS-
CoV-2 (56). 
 
Public health control measures 
How it all started 
The fast dynamics of Wuhan, a bustling city of 11 
million residents with high population density, favoured 
the rapid transmission of COVID-19 at its earliest stage 
(53). A banquet in Wuhan for 400,000 guests that was 
held immediately before the lockdown is also believed 
to have fuelled the transmission (53). By the time the 
outbreak was detected, community transmission was 
imminent, forcing the lockdown of Hubei province. 
Countries subsequently affected by the outbreak have 
employed different levels of control measures 
depending on the epidemiologic pattern of the outbreak 
and the local socioeconomic circumstances. 
 
Epidemiologic parameters and control measures 
More than two thirds of countries in the world are taking 
serious measures to control the COVID-19 pandemic 
following the surge in disease transmission and the loss 
of tens of thousands of lives. Designing effective 
outbreak control measures requires a good 
understanding of the course of the disease and accurate 
estimates of the epidemiologic parameters. The 
conventional isolation and contact tracing approach is 
recommended for a localized outbreak with minimal 
community transmission (54). This approach will be 
effective if two epidemiologic parameters are optimal: 
the basic reproductive number and the time to 
infectiousness (54). 
 
The basic reproductive number (R0) 
Basic reproductive number (R0) stands for the number 
of secondary cases developed following contact with the 
infectious patient. It is estimated from mathematical 
models, taking into account the varying environmental- 
and patient-related factors that can modify transmission. 
An R0 value of 1 indicates steady transmission. An R0 
value of less than 1 indicates a decline in transmission. 
A R0 value >1 is consistent with an outbreak or 
indicative of a highly likely outbreak. An accurate 
estimate of R0, especially for a new disease, will be 
obtained if the estimation is done once the outbreak is 
through its course. This way we can account for the total 
number of cases that occurred during the outbreak (54). 
 
We have found few publications on basic reproductive 
number for COVID-19 from studies conducted 1-2 
months after the outbreak. The studies have provided 
varying estimates of R0 values for the outbreak. The first 
study involved 24 provinces in China with a minimum 
of 100 confirmed cases (55). In this study, the final R0 
estimate obtained after updating the model a few times 
was <1 (55). The basic assumption when calculating R0 
is a complete absence of control interventions and the 
whole population is susceptible to the infection (54). 
Nonetheless, when the above study was conducted, 
aggressive control measures were under way. Therefore, 
it is safe to assume that the R0 value could have been 
higher if those measures had not been in place. But this 
drawback was addressed in another study, where the 
investigators modelled the transmission based on data 
from the passengers of the Diamond Princess cruise 
ship. There were 3,711 people on board when the 
outbreak was detected among the passengers (56). This 
study has estimated a median R0 value of 2.28, which is 
significantly higher than the previous study, but lower 
than estimates from other studies (R0=3.58) (57). The 
estimate from the Diamond Princess cruise ship study is 
likely to be more accurate because it was conducted in a 
close to ideal setting to estimate R0. The complete 
control over the movement of people on and off the ship, 
the ability to avoid potential animal to human 
transmission, and being able to account for the level of 
control measures taken, are important to maximize the 
accuracy of the estimate (56). 
 
The generation time 
The second important parameter is the generation time. 
This is the time interval between the infection of the 
source and the generation of secondary cases (54). The 
isolation and contact tracing approach works best in 
diseases where the generation time overlaps with or 
exceeds the incubation period. In this scenario, people 
will have time to isolate themselves and health 
personnel can screen patients before the disease 
transmits (58).  
 
Epidemiologists attribute the effective control of the 
2002 SARS outbreak to the nature of the infection where 
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the infectiousness hits peak after the onset of disease 
symptoms. This made the isolation and contact tracing 
interventions effective, leading to control before it had 
impacted on more nations (59). However, evidence on 
the generation time of COVID-19 is lacking and this 
undermines the effectiveness of the control 
interventions (60).  
 
A study of 17 symptomatic COVID-19 patients 
indicated higher viral load in the nasal and throat swab 
specimens right after the onset of symptoms. This 
indicates the possibility of transmission earlier in the 
course of the infection, even before the onset of the 
symptoms (61,62). Viral load in the asymptomatic 
patients was comparable to viral load in the 
symptomatic patients (61). This finding is crucial, 
mainly because 30% of the people who are positive for 
COVID-19 infection are asymptomatic (57). These 
important epidemiologic characteristics make it clear 
that employing isolation and contact tracing solely are 
not enough to control the outbreak. A mathematical 
model showed that if we employ isolation and contact 
tracing as the only control strategy, one should trace and 
isolate 80% of contacts of each patient to achieve a 
probability of 90% control in three months’ time, 
assuming a 2.5 basic reproductive number (58).  
 
These findings unequivocally indicate that using only 
one conventional outbreak control approach is simply 
inadequate to control the COVID-19 pandemic. 
Countries need a combination of various interventions 
implemented with the utmost efficiency and central 
coordination (63). Extensive physical and social 
distancing interventions with increased and regular hand 
washing practices, coupled with isolation and contact 
tracing, can improve the likelihood of control in the 
foreseeable future. Social distancing (if done correctly) 
alone can reduce transmission by 60% given the 
outbreak is at its early stage (62). But at later stages, 
after community transmission is witnessed, the 
intervention should progressively scale to community 
containment. 
 
This recommendation holds true for Ethiopia as well. In 
the past three weeks (counting from April 15, 2020), 85 
confirmed cases have been reported. All except a few 
came from abroad or had contact with people who had 
recently arrived from overseas (28). Considering the 
short doubling time (4-5 days) of the outbreak, 85 cases 
over a week’s period is encouraging (62). On the other 
hand, it could be suggestive of inadequate testing. Up 
until we prepared this report, only 700 people who were 
deemed to have a close contact with confirmed cases had 
been tested. The limited testing and the unclear course 
of the disease portend a rapid increase in the number of 
cases any time soon. Therefore, the number of tests 
should increase to aid the effectiveness in the 
implementation of isolation and contact tracing, social 
distancing and related public health interventions. 
 
The use of face masks as a preventive measure 
When we prepared this report, the WHO maintains that 
there is no evidence showing the effectiveness of 
wearing masks in reducing the transmission of the virus 
(30,43,58), although there is a separate WHO 
recommendation that states wearing a medical mask is 
one of the preventive measures to limit the spread of 
certain respiratory diseases, including COVID-19 (43). 
Despite recommendations that the use of face masks 
should be restricted to health professionals only, the 
absence of evidence regarding their effectiveness among 
the general public does not prove their ineffectiveness, 
especially when facing an outbreak with limited control 
alternatives (59). Moreover, viruses can also transmit 
through the eyes and tiny viral particles, known as 
aerosols, which can penetrate masks, although some 
argue that masks are effective at capturing droplets, 
which is a main transmission route of coronavirus (60). 
Furthermore, since there is asymptomatic and pre-
symptomatic transmission, the universal use of masks 
contributes to a decrease in the transmission (59,61). 
Though the WHO’s stance on the universal use of face 
mask is unclear at the time, it has called for a 40% 
increase in the production of protective equipment (62).  
 
The Ethiopian Ministry of Health has been 
recommending symptomatic individuals and health care 
providers should wear masks. But the latest directive 
also encourages the use of cotton masks by the rest of 
the population, especially in public places.  
 
The use of alcohol hand sanitizers  
Hand hygiene is one of the main preventive measures in 
response to COVID-19 (63,64). Washing hands often 
with soap and water for at least 20 seconds is essential. 
If soap and water are not readily available, the CDC 
recommends consumers use an alcohol-based hand 
sanitizer that contains at least 70% alcohol (also referred 
to as ethanol or ethyl alcohol). Since health care 
professionals are having problems accessing alcohol-
based sanitizers, the CDC has provided a policy guide 
for compounding them. As the COVID-19 outbreak is a 
public health emergency, the FDA announced it does not 
intend to take action against compounders who prepare 
alcohol-based hand sanitizers for consumers and hand 
rubs for health care personnel for the duration of the 
public health emergency, as long as the requirements are 
met (65). 
 
With hand sanitizers in short supply and the increasing 
number of COVID-19 cases, it is essential to locally 
produce alcohol-based hand rub formulations with 
guidelines available in local settings (66).  
 
Psychosocial interventions for health care providers 
The WHO has developed key recommendations on 
mental health considerations for the general population, 
health workers, including team leaders and health 
facility managers, care providers, and people with 
underlying health conditions (67). 
 
In relation to health workers, the recommendations 
focus on normalizing the experience of stress, the need 
for employing healthy coping strategies (adequate sleep, 
healthy eating, exercise and staying in touch with loved 
ones), equipping oneself with the required knowledge, 
and managing possible stigma. Team leaders are 
encouraged to protect their staff from chronic stress, 
clearly communicate with staff, encourage staff to 
provide mutual support, and ensure the availability of 
COVID-19: Initial synthesis of the epidemiology, pathogenesis, diagnosis, treatment      137 
 
Ethiop. J. Health Dev.2020; 34(2) 
essential, generic psychotropic medications at all levels 
of health care. 
 
Mindfulness-based stress reduction is one of the 
recommended techniques to cope with stress (68). There 
is evidence that mindfulness has a great potential to 
reduce stress, anxiety and burnout (69).  
 
Discussion 
The epidemiology and nature of COVID-19 are 
changing. In this rapid review, we have tried to 
synthesize what is known about the disease, the 
causative pathogen and treatment, and prevention 
strategies employed at the time this review was 
conducted (April 15, 2020). The pandemic has affected 
both developed and developing countries, 
overwhelming health systems and challenging 
economies, and it is now threatening to engulf Africa. 
Gender, cigarette smoking and underlying disease 
conditions are associated with unfavourable outcomes. 
A reverse real-time polymerase chain reaction assay is 
used for diagnosis, but no vaccine or treatment has been 
discovered to treat the infection. Most countries have 
taken progressively stringent measures of control with 
the hope of averting the impending calamity. This 
review, by summarizing the key evidence regarding the 
seriousness of the threat, the resources for treatment, 
diagnosis, prevention, and control, hopes to assist in the 
effort to avert the pandemic.  
 
Although the symptoms are consistent with atypical 
upper respiratory tract infection and atypical 
pneumonia, the information is based on the experience 
of China and developed countries. There is a need to 
systematically describe the clinical features and course 
of COVID-19 in Ethiopia and other countries in Africa. 
There may be variations in presentation because of host 
and pathogen factors. In relation to host factors, people 
in Africa have a somewhat different co-morbidity 
profile, age distribution, economic and nutritional 
factors and service use practices that may affect the 
presentation and course of the illness.  
 
Age and co-morbidities may be of particular interest 
because they predict disease severity and death (70). 
COVID-19-related risk of deaths is 1.4% and it 
increases with age (23). Communities with a high 
proportion of aging population have suffered the wrath 
of the pandemic. This has been particularly 
demonstrated in Germany and Italy. Germany, with a 
significantly low number of deaths has  two thirds of the 
patients in the age range of 35 to 50, with only 19% older 
than 60 years (71), while in Italy there have been much 
higher numbers of older people affected and the death 
toll was also higher. For Africa, the much lower 
proportion of people older than 60 may translate into 
fewer deaths, although Africa’s weak health systems 
may increase vulnerability. Therefore, strong control 
interventions should be directed towards protecting the 
elderly (72). 
 
Though we still do not have concrete evidence, chronic 
infectious diseases such as tuberculosis (TB) and 
HIV/AIDS, as well as chronic undernutrition, may 
increase the risk of death secondary to COVID-19. As 
these conditions are prevalent in the developing world, 
COVID-19 control measures should consider the 
increased risk among these groups of people (73). 
Strategies to carry out the follow-up of patients with 
chronic diseases and TB remotely may reduce the risk 
of exposure at medical facilities.  
The reverse real-time polymerase chain reaction is a test 
currently in use to diagnose SARS-CoV-2 infection. 
Though this test has a high diagnostic accuracy, it 
requires well-trained technologists, sound laboratory 
facilities and multiple reagents (74). This makes the test 
ill fit to deal with a pandemic of this scale and nature. 
Currently, simpler POC antibody tests are under 
development (75). Such simple tests will make large-
scale community-based screening feasible, even in the 
under-developed and under-resourced parts of the 
world. The number of available tests (assuming it is 
conducted at the right time) determines nations’ ability 
to control the pandemic (74). Therefore, developing 
countries should be encouraged and supported to locally 
produce such less expensive and easier-to-use antibody 
tests. 
 
The world is uncertain about what the future holds (76). 
Vaccinating a significant proportion of the population 
creates herd immunity, breaking the chain of 
transmission (77). The large number of vaccine trials 
under way (78) encourages the hope that vaccine 
development will be completed in the coming 12 to 18 
months. The challenge seems, given the need to produce 
the vaccine in large amounts at one time, how the 
vaccine can be allocated in a fair way. The experience 
from previous flu-like pandemics suggests that the 
developing world needs to be vigilant. Cautious steps 
should be taken not to widen the already existing rift 
between high-income and low-income countries in 
relation to access to vaccines (79).  
 
So far there is no robust evidence for effective treatment 
against SARS-CoV-19. While the need for a rapid 
development of treatment cannot be disputed, caution 
must be exercised in providing compassionate 
treatments or conducting clinical trials to avoid 
additional risks to patients. In the absence of clear 
evidence, the trade-off in shifting drugs which were 
originally intended to treat other diseases to COVID-19 
patients should also be considered. Therefore, clinical 
trials should be conducted to account for the safety and 
efficacy of repurposed drugs. 
 
Health care personnel are invaluable resources in the 
fight against the pandemic. As first responders, they face 
an exceptional risk of contracting the infection. Thus, 
protecting their wellbeing is paramount. This extends 
from making the needed personal protective equipment 
and testing available to ensuring their psychosocial and 
physical wellbeing. For the general public, although 
directives on face mask use are fluid, we strongly 
recommend that the universal use of face masks will 
help control the outbreak by reducing escape of the virus 
from infected people. To avoid stockout of medical 
masks restricting the general public (non-health care 
providers) to using cotton face masks only can be 
considered. 
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While we believe that this review offers important 
information on a broad range of issues relevant to 
understanding the pathogen, the magnitude of illness 
and the status of knowledge about treatment and control, 
the primary data collected is mostly anecdotal, and 
report- and opinion-based. Additionally, knowledge 
about COVID-19 is extremely fluid. For example, the 
data on the magnitude of the disease provides the overall 
trend and level of threat; this will have changed 
substantially by the time this paper is published. The 
recommendations on treatment and diagnosis are 
unlikely to change, although better POC diagnostics 
might be, if produced by the time this paper is published. 
The possible methodologic drawbacks with such 
publications and the ever-changing science surrounding 
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